Fines, approvals and anniversaries...What’s new in business?
Maryam Mahdi |
This article was published in our sister publication, The Small Molecule Manufacturer, which celebrates the field of small molecule drug development and manufacturing with interviews and articles focusing on success stories, equipment, and new processing techniques. Read more about The Small Molecule Manufacturer here https://themedicinemaker.com/manufacture/small-but-never-forgotten
- GSK’s decision to delay the market availability of paroxetine, an antidepressant, could be considered anti-competitive, Juliane Kokot, a legal advisor to the European Court of Justice (ECJ) has warned. The company was previously hit with a £37.6 million fine in 2016 for the “pay-for-delay” deals it had cut with generic companies.
- Novo Nordisk’s blockbuster drug, Ozempic, a medication that stimulates insulin production in Type II diabetics, has won extended label approval from the FDA. The expansion was granted due to the drug’s ability to treat cardiovascular disease, non-fatal heart attack and non-fatal stroke in patients living with Type II diabetes.
- The European Medicines Agency (EMA) celebrated its 25th anniversary on January 27. Guido Rasi, the EMA’s Executive Director commended the work of the agency in a recent statement: “25 years is a significant milestone for EMA. Together with our partners and stakeholders from national authorities, EU institutions and civil society, we harmonized and improved medicines’ evaluation, stimulated innovation, improved safety monitoring and management, fostered transparency and dialogue, built relationships with international partners, and helped to make medicines accessible to those who need them.”
- Colorcon has received an EXCiPACT GMP and GDP Certificate from SGS, one of EXCIPACT’s internationally recognized certification bodies. The certificate was awarded to Colorcon for its Westpoint site in Pennsylvania, US for its capacity to manufacture and distribute lake pigments (wet and dry) and polyvinyl acetate phthalate (phthalin-coating materials) for use as pharmaceutical excipients.
Enjoy our FREE content!
Log in or register to gain full unlimited access to all content on the The Medicine Maker site. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.